StrongDecrease
Blood pressure reduction
Tirzepatide → Blood pressure reduction
Tirzepatide → Blood pressure reduction
Evidence profile
StrongDecreaseMetabolic Health
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Tirzepatide improves weight loss in adults with type 2 diabetes
Key finding
Body weight reduction of ≥15% with tirzepatide.
This study investigated factors associated with body weight reduction in adults with Type 2 diabetes using tirzepatide, finding that higher doses led to greater weight loss.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
High bias
Last updated July 4, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Tirzepatide 5 mg, Tirzepatide 10 mg, Tirzepatide 15 mg
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Primary outcome
Body weight reduction
Comparator
Placebo Control
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study investigated factors associated with body weight reduction in adults with Type 2 diabetes using tirzepatide, finding that higher doses led to greater weight loss.
Clinical relevance
These findings are significant for clinicians treating patients with Type 2 diabetes, as effective weight management can lead to better overall health outcomes. Understanding the dose-response relationship of tirzepatide can help tailor treatments to individual patient needs, potentially improving adherence and long-term success.
Keep in mind
The study's effectiveness results were unclear due to unspecified p-values. Limited generalizability due to the specific population studied. Potential unmeasured confounders affecting outcomes.
Published in
Journal Reference
Publication details and source links for this paper.
Maciej TM, Rachel LB, Naveed S, et al. Factors Associated with Body Weight Reduction with Tirzepatide in Adults with Type 2 Diabetes. Diabetes Care. 2023;46(12):2292-2299. doi:10.2337/dc23-1135
Save this study and add notes to your research library.
Main Effects
Body weight reduction of ≥15% was significantly associated with higher tirzepatide doses.
Greater reductions in HbA1c were observed with higher categorical weight reductions.
Higher categorical weight reductions led to significant decreases in triglycerides.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Tirzepatide and Blood pressure reduction, Body weight, HbA1c, and 2 more.
This study contributes evidence to
Primary intervention
Tirzepatide
Primary outcomes
- Blood pressure reduction
- Body weight
- HbA1c
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
5
Evidence pairs
291
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
StrongDecrease
Body weight
Tirzepatide → Body weight
Tirzepatide → Body weight
Evidence profile
StrongDecreaseWeight & Anthropometrics
Unlock full evidence details
StrongDecrease
HbA1c
Tirzepatide → HbA1c
Tirzepatide → HbA1c
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
StrongDecrease
Triglycerides
Tirzepatide → Triglycerides
Tirzepatide → Triglycerides
Evidence profile
StrongDecreaseMetabolic Health
Unlock full evidence details
StrongDecrease
Waist circumference
Tirzepatide → Waist circumference
Tirzepatide → Waist circumference
Evidence profile
StrongDecreaseWeight & Anthropometrics
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Participants experienced an average weight loss of -18.5 kg.
- HbA1c levels decreased by -2.6% with higher weight reductions.
- Triglycerides also showed significant reductions with increased weight loss.
Who this applies to
- Adults diagnosed with Type 2 diabetes.
- Patients seeking weight management solutions.
Keep in Mind
- Results may not apply to populations outside the study's demographic.
- The study did not clarify the statistical significance of all findings.
- Further research is needed to explore long-term effects of tirzepatide.
Between the Lines
- The study's effectiveness results were unclear due to unspecified p-values.
- Limited generalizability due to the specific population studied.
- Potential unmeasured confounders affecting outcomes.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
8 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
8 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
7 studies
outcome_hubMeasures Body Weight as a key outcome.
Blood Pressure Evidence Hub
All studies measuring Blood Pressure
1 studies
outcome_hubMeasures Blood Pressure as a key outcome.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Tirzepatide and HbA1c
Intervention: TirzepatideOutcome: HbA1c
8 results
All studies on Tirzepatide and Body weight
Intervention: TirzepatideOutcome: Body weight
7 results
All studies on Tirzepatide
Intervention: Tirzepatide
8 results
All studies measuring HbA1c
Outcome: HbA1c
8 results
All studies measuring Body weight
Outcome: Body weight
7 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Weight.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 82.5 | strong positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 23 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.1 | strong positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 24 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve adipokine and angiogenic markers?
Strong Evidence
GLP-1 Receptor Agonists appears to improve Adipokine and Angiogenic Markers.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Triglycerides
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 7 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve body composition?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Composition.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Waist circumference
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetesTirzepatide improves glycemic control in early-onset type 2 diabetesMediterranean ketogenic eating matched VLCKD for weight loss over 3 monthsTirzepatide enhances insulin sensitivity in type 2 diabetesSwitching to tirzepatide from dulaglutide improved HbA1c and weight across baseline characteristics
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.